CDO / CAIO Guide for AI in Pharma
The Decision Desk · CDO / CAIO Guide · AI in Pharma · September 2026 Edition
Twelve Decisions
From Data Platformto Pharma Decision Infrastructure.
Twelve questions on ontology, architecture, autonomy, governance and compounding intelligence that determine whether AI becomes proprietary advantage in Pharma, not just proprietary spend.
Takes 30 seconds. No spam, just The Decision Desk, weekly.
What's inside the guide
01Strategy: what should our AI strategy actually optimise for?
02Data foundation: what does AI actually require?
03Ontology: why should it become core to the architecture?
04Proprietary advantage: what stays ours as models commoditise?
05Build, buy, partner: what goes where?
06Architecture: how do RAG, graphs, causal reasoning and agents fit?
07Operating model: centralised or federated?
08Funding: which bets deserve disproportionate capital?
09Autonomy: how autonomous should AI become?
10Governance: how should it change?
11People: what happens as AI scales?
12Compounding value: how does AI get more valuable every year?
12 CDO/CAIO-level questions
From the Enterprise Decision Portfolio to ontology, build/buy/own, autonomy and governance.
A full target architecture
The seven-layer stack from systems of record to the experience layer, with Enterprise Context at its centre.
A 12-month agenda
Concrete moves for 0 to 90 days, 3 to 6 months, and 6 to 12 months, not a five-year programme.
“
68% of pharma and biotech leaders cite neglecting data quality and governance early as the main reason AI initiatives fail.
ZS, 2026 CDIO Outlook · cited in the guidePart of a 5-week series · Week 2 of 5
This is Week 2 of DecisionX's September series on Decision AI in Pharma, covering the CEO agenda, this CDO/CAIO architecture guide, Commercial Excellence, Manufacturing Excellence, R&D Excellence, and a closing case study on what this actually returns.
The Decision Desk · CDO / CAIO Guide
CDO/CAIO Guide for AI in Pharma
Twelve questions. One architecture. Free, no spam, no sales pitch first.
Backed by ZS, Gartner, Deloitte and MIT NANDA research